NanoString® Technologies is a publicly held provider of life science tools for translational research and molecular diagnostics. They are committed to providing tools that enable scientists and clinicians to translate today’s leading research into clinically actionable tests that improve patient care.
NanoString's products are based on a novel digital molecular barcoding technology. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection, and in 2013 launched Prosigna™, its first in vitro diagnostic product for prognosis of early stage breast cancer.
The nCounter® Analysis System is an automated, multi-application, digital detection and counting system which directly profiles up to 800 molecules simultaneously from a single sample using a novel barcoding technology.
Pathway-based Translational Research
Gene Expression Analysis
Single Cell Gene Expression Analysis
lncRNA Expression Analysis
Leukemia Fusion Gene Analysis
miRNA Expression Analaysis
miRGETM Expression Analysis
Copy Number Variation Analysis
ChIP-String Expression Analysis
ProsignaTM Breast Cancer Gene Signature Assay
Link to NanoString® Technologies